A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
Crossref DOI link: https://doi.org/10.1186/s40064-015-1601-7
Published Online: 2016-01-19
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gunzer, Katharina
Joly, Florence
Ferrero, Jean-Marc
Gligorov, Joseph
de Mont-Serrat, Helene
Uttenreuther-Fischer, Martina
Pelling, Katy
Wind, Sven
Bousquet, Guilhem
Misset, Jean-Louis
License valid from 2016-01-19